Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer

  • End date
    Jan 12, 2024
  • participants needed
  • sponsor
    Bobbie Jo Rimel, MD
Updated on 12 May 2022


This is a single arm pilot trial to evaluate the feasibility of using a simvastatin intervention, and to evaluate its effects on cancer progression, among 20 patients with platinum-sensitive ovarian cancer, treated with carboplatin and liposomal doxorubicin at Cedars-Sinai Medical Center.


This is a pilot study of statin therapy to examine the feasibility of simvastatin use to reduce disease progression in 20 patients with platinum-sensitive ovarian cancer at Cedars-Sinai Medical Center. This study will focus on patients with recurrent platinum sensitive ovarian cancer to increase the likelihood that this population will experience recurrent disease during the 6-month intervention and follow-up. In addition, this population of patients has a narrow range of standard of care carboplatin doublet combinations that are prescribed, enabling the investigators to create a more homogenous study population. Given their high risk of developing recurrent disease, women with platinum sensitive ovarian cancer, have the potential to derive the maximum benefit from an intervention that could delay disease progression and enhance survival.

Condition Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer
Treatment simvastatin 40mg
Clinical Study IdentifierNCT04457089
SponsorBobbie Jo Rimel, MD
Last Modified on12 May 2022


Yes No Not Sure

Inclusion Criteria

Recurrent platinum sensitive ovarian cancer, all histologies (serous, endometrioid, mucinous, clear cell). Platinum sensitivity defined as ≥ 6 months since last platinum treatment
No contraindication to carboplatin and/or liposomal doxorubicin or simvastatin

Exclusion Criteria

Prior or current use of any statin medication
Current systemic use of medications known to interact with statins
Current use of any other investigational agents
Liver disease, active cirrhosis
Uncontrolled intercurrent illness
History of chronic myopathy
Prior cancer other than ovarian cancer or non-melanomatous skin cancers
Known active infection with HIV
Current excessive alcohol consumption (average alcohol consumption of more than 5 drinks per day)
Prior exposure to doxorubicin or liposomal doxorubicin
Hemoglobin A1C >8.0%
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note